# A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects

> **NCT04250506** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Daridorexant
- **DRUG:** Placebo
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT04250506
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-28
- **Primary completion:** 2020-07-22
- **Final completion:** 2020-07-22
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04250506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04250506, "A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04250506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*